U.S. FDA Assessing Capability To Amplify Surveillance Of Indian, Chinese OTC Manufacturers - PharmAsia Summit
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is gathering information to sharpen its risk-assessment approach and determine inspection priorities for nutraceuticals and traditional medicine manufacturers that use a registration loophole to export products to the U.S. under less-stringent oversight.
You may also be interested in...
U.S. FDA China Country Head Chris Hickey On FDA's Mission In China: An Interview With PharmAsia News (Part 2 of 2)
U.S.FDA established offices in China in 2008 to improve oversight of products exported to the U.S., and to establish stronger working relationships with China's State FDA. The mission of the office initially was to implement two export agreements signed with China in December 2007 to enhance regulatory cooperation in the areas of food, drugs, medical devices and animal feed. PharmAsia News' China and Australia bureaus spoke to FDA China Country Director Christopher Hickey about the mission of the China office and progress being made in China. This is part two of a two-part interview; part one appeared in a recent issue of PharmAsia News.
U.S. FDA Commissioner Hamburg Promotes Regulatory Science Collaboration In China Visit
SHANGHAI - China is predicted to become the world's second largest economy by the end of this year, and last week, U.S. FDA Commissioner Margaret Hamburg made her first trip to China to boost communication with China's State FDA and to emphasize that the relationship between the U.S. and China has become more important than ever
FDA Foreign Inspections To Double In 2010, Led By Human Drugs And Food
FDA will shoot to double its inspections of foreign facilities in fiscal 2010 to more than 2,000